Compounding with Sarah

  Prostaglandin Analogues for Alopecia: Considerations for the use of Latanoprost or Bimatoprost By Sarah Taylor, PharmD Prostaglandin analogues such as bimatoprost or latanoprost have historically been used ophthalmically, where they are FDA approved for the use of elevated intraocular pressure. Bimatoprost 0.03% has also been approved for the management of hypotrichosis of the eyelashes. The mechanism of action is prostaglandin analogues interact with prostanoid receptors in the hair follicle. This is thought to stimulate resting follicles in the telogen phase and convert them to the anagen phase (associated with hair growth). 3 This same mechanism of action that increases eyelash growth is thought to be responsible for the growing data to support the use of prostaglandin analogues topically on the scalp for alopecia. Data Regarding Alopecia of the Scalp Latanoprost has been studied at a very wide range of concentrations. One double-blind placebo controlled study on topical

  Interpreting USP <800> Table 2 Primary Engineering Controls By Bryan Prince USP <800> is a relatively short document but packed with so much detail, requiring quite a bit of technical thinking and explanation, especially as it relates to the subject of engineering controls.   Pharmacists are not engineers, so one of the first questions is, how do I interpret Table 2. Engineering Controls for Nonsterile HD Compounding ? First, let’s dissect the two categories of engineering controls listed in Table 2.   The “C-PEC” is the containment primary engineering control, which is another name for a “powder hood”, also called a containment ventilated enclosure (CVE).   The table also lists other types of primary engineering controls, but for the sake of this discussion we will only focus on the most common type of hood found in a nonsterile compounding pharmacy.   The C-PEC will have either one single HEPA filter (see Figure-1) or two HEPA filters, also called “redundant-H

  Excipients for Hard-shell Capsules: Why Cellulose is Not Enough By Hudson Polonini,  BPharm MSc PhD Excipients are essential ingredients for a solid oral dosage form’s good performance, ensuring correct bioavailability, solubility, stability and dose accuracy. Therefore, choosing the right excipient is paramount for the adequate clinical performance of a robust dosage form. This choice needs to be based on technical parameters of both the active pharmaceutical ingredient (API) and the functionality of the dosage form itself – therefore science needs to be on the backbone of such process. As an example of the importance of the excipient’s role on the dosage form performance, we can consider the case of an intoxication that occurred in Australia in the late 1960s: epileptic patients who were taking phenytoin capsules experienced intoxications due to the replacement of the diluent. Calcium sulphate was changed to lactose, and this led to an increase of the mean serum concentration